The purpose of this workshop is to review novel technologies, to identify which characteristics should be prioritized, how to meet regulatory requirements, and how to move from innovation to market.
Despite advances in diagnostics for flaviviral infections, there is a critical need for more sensitive, specific, easy to use and affordable tests for point of care (POC) diagnosis, multiplex virologic and serologic assays to differentiate co-circulating viruses of public health significance, eg, dengue, Zika, yellow fever and chikungunya, and methods for viral quantification and genomic characterization. New diagnostic methods continue to be innovated, such as microfluidics, paper-based diagnostics, chip-based systems, micro- and nanofabrication technologies, deep sequencing, among others.
Towards the development of new technologies
The Partnership for Dengue Control (PDC) wishes to cast a wider net to facilitate and expedite the development of the most promising technologies that are urgently needed not only for pressing research questions but also to be rolled out in affected countries. The Flavivirus field can learn from cutting-edge technologies that have been developed for diseases such as HIV, malaria and Tuberculosis. Hence the workshop is organized around three questions:
What is the current status of Zika and dengue diagnostics?
What new technologies might be available in the near, intermediate and long-term future?
What is needed to make these technologies available?
Chairs
May Chu, Colorado School of Public Health, Clinical Professor
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Scientific Committee
Arlene Chua, World Health Organization, Technical Consultant
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Eva Harris, University of California, Berkeley, Professor
Aravinda de Silva, University of North Carolina School of Medicine, Professor
Bernadette Murgue, WHO, R&D Blueprint manager
Maurine Murtagh, The Murtagh Group, LLC Principal
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Organized by the Partnership for Dengue Control (PDC) and the Mérieux Foundation (France), with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur.
Setting the objectives of the meeting – Annelies Wilder-Smith, PDC
What are the necessary characteristics of diagnostic assays depending on the intended use: case management, surveillance, serosurveys, research studies, intervention trials – Duane Gubler, GDAC
Review of Zika standard assays (CDC MAC, IgG and PRNT) – Aravinda de Silva for Amy Lambert, CDC
Landscape analysis of the current status of Flavivirus diagnostics (dengue and Zika) – Maurine Murtagh, The Murtagh Group
Coffee break
3.30pm – 5pm
Session 2
Chairs: Francis Moussy, Amy Lambert
Learning from successful novel technologies that made it to the market – Mark Miller, BioMerieux
Demand forecasting and market considerations – Nagwa Hasanin, UNICEF
Learning from past emergency authorizations – Elliot Cowan, Partners in Diagnostics
Networking session
6.00pm – 7.00pm
Evening Chair: May ChuTalk: Zika and dengue diagnostics from a strategic investor’s perspective – Julie Schäfer, BARDA
Cocktail Dinner
Wednesday, May 3 – Day 2
Where do we go? Technological innovations in Flavivirus diagnostics
8.30am – 12.30pm
Session 3: Detecting acute infection
Chairs: Maurine Murtagh, Arlene Chua
Imminent technological innovations
Cutting edge innovations for the intermediate and long-term future
Discussion
8.30am – 10.00am
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University
Development of molecular tests for management of febrile illnesses and diagnosis of viral haemorrhagic fever – Kevin Arien, ITM
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences
Coffee break
10.30am – 12.30pm
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH
Application of a parsimonious targeted-enrichment methodology for full-genome sequencing of viral genomes directly from patient samples – October Sessions, Duke-NUS
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS
Multiplex magneto-optical detection technique – John Lewandowski, MIT
Discussion
Lunch
2pm – 5.45pm
Session 4: Detecting past infections
Chairs: Eva Harris, Aravinda de Silva
2pm – 3.40pm
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University
Structure based design of novel Zika virus antigens for serodiagnosis – Prem Lakshmanane, UNC-CH, North Carolina
Coffee Break
4.00pm – 5.00pm
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux
VIRO-TRACK – A rapid, quantitative, and accurate dengue/zika diagnostics platform for point of care use in endemic regions – Filippo Giacomo Bosco, BluSense Diagnostics ApS
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA
5.00pm – 5.45pm
Discussion
BBQ
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
8.30am – 10am
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response
Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint
Diagnostics preparedness platform – Thomas Ullrich, Alere
Learning from influenza POCT – Julie Schäfer, BARDA
Genetic analysis tool kit for rapid outbreak response – Michael Baffi, Thermo Fisher
Coffee break
10.30am – 12.30pm
Session 6: Critical steps to ensure quality products
Chairs: Rosanna Peeling, Piero Olliaro
Critical steps to ensure quality products – Bill Rodriguez
Lessons learnt on bringing diagnostics to the market in low and middle income countries – Cassandra Kelly, FIND
Two new WHO IVD initiatives: SAGE-IVD and EDL – Francis Moussy, WHO Blueprint
Regional regulatory harmonization working parties – Rosanna Peeling, LSHTM
Streamlining from bench-to-bedside – Piero Olliaro, WHO TDR
Panel Discussion
Lunch
1.30pm – 3:30pm
Session 7: Identifying PDC’s roles to support innovative diagnostics
Chairs: May Chu, Julie Schäfer
Panel 1: Networks and alliances – Dhamari Naidoo, WHO; Maria Guzman, RELDA Cuba; Amadou Sall, Institute Pasteur Senegal; Francois Xavier Babin, Merieux (Networks of Laboratories);
Annelies Wilder-Smith and In-Kyu Yoon, GDAC
Panel 2: Accelerating from ideas to market – Jennifer Fluder, USAID; Rosanna Peeling, LSHTM; Thomas Ullrich, Alere
Panel 3: Views from stakeholders and partners – Sumi Paranjape, Vulcan; Nagwa Hasanin, UNICEF; Julie Schäfer, BARDA
Concluding Discussion: research agenda and roadmap for the next 12 months
3.30pm – 4pm
Summary and Recommendations – May Chu, Rosanna Peeling and Annelies Wilder-Smith
Coffee Break
">
The purpose of this workshop is to review novel technologies, to identify which characteristics should be prioritized, how to meet regulatory requirements, and how to move from innovation to market.
Despite advances in diagnostics for flaviviral infections, there is a critical need for more sensitive, specific, easy to use and affordable tests for point of care (POC) diagnosis, multiplex virologic and serologic assays to differentiate co-circulating viruses of public health significance, eg, dengue, Zika, yellow fever and chikungunya, and methods for viral quantification and genomic characterization. New diagnostic methods continue to be innovated, such as microfluidics, paper-based diagnostics, chip-based systems, micro- and nanofabrication technologies, deep sequencing, among others.
Towards the development of new technologies
The Partnership for Dengue Control (PDC) wishes to cast a wider net to facilitate and expedite the development of the most promising technologies that are urgently needed not only for pressing research questions but also to be rolled out in affected countries. The Flavivirus field can learn from cutting-edge technologies that have been developed for diseases such as HIV, malaria and Tuberculosis. Hence the workshop is organized around three questions:
What is the current status of Zika and dengue diagnostics?
What new technologies might be available in the near, intermediate and long-term future?
What is needed to make these technologies available?
Chairs
May Chu, Colorado School of Public Health, Clinical Professor
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Scientific Committee
Arlene Chua, World Health Organization, Technical Consultant
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Eva Harris, University of California, Berkeley, Professor
Aravinda de Silva, University of North Carolina School of Medicine, Professor
Bernadette Murgue, WHO, R&D Blueprint manager
Maurine Murtagh, The Murtagh Group, LLC Principal
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Organized by the Partnership for Dengue Control (PDC) and the Mérieux Foundation (France), with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur.
Setting the objectives of the meeting – Annelies Wilder-Smith, PDC
What are the necessary characteristics of diagnostic assays depending on the intended use: case management, surveillance, serosurveys, research studies, intervention trials – Duane Gubler, GDAC
Review of Zika standard assays (CDC MAC, IgG and PRNT) – Aravinda de Silva for Amy Lambert, CDC
Landscape analysis of the current status of Flavivirus diagnostics (dengue and Zika) – Maurine Murtagh, The Murtagh Group
Coffee break
3.30pm – 5pm
Session 2
Chairs: Francis Moussy, Amy Lambert
Learning from successful novel technologies that made it to the market – Mark Miller, BioMerieux
Demand forecasting and market considerations – Nagwa Hasanin, UNICEF
Learning from past emergency authorizations – Elliot Cowan, Partners in Diagnostics
Networking session
6.00pm – 7.00pm
Evening Chair: May ChuTalk: Zika and dengue diagnostics from a strategic investor’s perspective – Julie Schäfer, BARDA
Cocktail Dinner
Wednesday, May 3 – Day 2
Where do we go? Technological innovations in Flavivirus diagnostics
8.30am – 12.30pm
Session 3: Detecting acute infection
Chairs: Maurine Murtagh, Arlene Chua
Imminent technological innovations
Cutting edge innovations for the intermediate and long-term future
Discussion
8.30am – 10.00am
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University
Development of molecular tests for management of febrile illnesses and diagnosis of viral haemorrhagic fever – Kevin Arien, ITM
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences
Coffee break
10.30am – 12.30pm
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH
Application of a parsimonious targeted-enrichment methodology for full-genome sequencing of viral genomes directly from patient samples – October Sessions, Duke-NUS
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS
Multiplex magneto-optical detection technique – John Lewandowski, MIT
Discussion
Lunch
2pm – 5.45pm
Session 4: Detecting past infections
Chairs: Eva Harris, Aravinda de Silva
2pm – 3.40pm
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University
Structure based design of novel Zika virus antigens for serodiagnosis – Prem Lakshmanane, UNC-CH, North Carolina
Coffee Break
4.00pm – 5.00pm
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux
VIRO-TRACK – A rapid, quantitative, and accurate dengue/zika diagnostics platform for point of care use in endemic regions – Filippo Giacomo Bosco, BluSense Diagnostics ApS
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA
5.00pm – 5.45pm
Discussion
BBQ
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
8.30am – 10am
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response
Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint
Diagnostics preparedness platform – Thomas Ullrich, Alere
Learning from influenza POCT – Julie Schäfer, BARDA
Genetic analysis tool kit for rapid outbreak response – Michael Baffi, Thermo Fisher
Coffee break
10.30am – 12.30pm
Session 6: Critical steps to ensure quality products
Chairs: Rosanna Peeling, Piero Olliaro
Critical steps to ensure quality products – Bill Rodriguez
Lessons learnt on bringing diagnostics to the market in low and middle income countries – Cassandra Kelly, FIND
Two new WHO IVD initiatives: SAGE-IVD and EDL – Francis Moussy, WHO Blueprint
Regional regulatory harmonization working parties – Rosanna Peeling, LSHTM
Streamlining from bench-to-bedside – Piero Olliaro, WHO TDR
Panel Discussion
Lunch
1.30pm – 3:30pm
Session 7: Identifying PDC’s roles to support innovative diagnostics
Chairs: May Chu, Julie Schäfer
Panel 1: Networks and alliances – Dhamari Naidoo, WHO; Maria Guzman, RELDA Cuba; Amadou Sall, Institute Pasteur Senegal; Francois Xavier Babin, Merieux (Networks of Laboratories);
Annelies Wilder-Smith and In-Kyu Yoon, GDAC
Panel 2: Accelerating from ideas to market – Jennifer Fluder, USAID; Rosanna Peeling, LSHTM; Thomas Ullrich, Alere
Panel 3: Views from stakeholders and partners – Sumi Paranjape, Vulcan; Nagwa Hasanin, UNICEF; Julie Schäfer, BARDA
Concluding Discussion: research agenda and roadmap for the next 12 months
3.30pm – 4pm
Summary and Recommendations – May Chu, Rosanna Peeling and Annelies Wilder-Smith
Coffee Break
" />
New and Innovative Approaches to Laboratory Diagnosis of Zika, Dengue and other Arboviruses - Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC)
April 28, 2017 - Les Pensières Center for Global Health, Veyrier du Lac, France
The purpose of this workshop is to review novel technologies, to identify which characteristics should be prioritized, how to meet regulatory requirements, and how to move from innovation to market.
Despite advances in diagnostics for flaviviral infections, there is a critical need for more sensitive, specific, easy to use and affordable tests for point of care (POC) diagnosis, multiplex virologic and serologic assays to differentiate co-circulating viruses of public health significance, eg, dengue, Zika, yellow fever and chikungunya, and methods for viral quantification and genomic characterization. New diagnostic methods continue to be innovated, such as microfluidics, paper-based diagnostics, chip-based systems, micro- and nanofabrication technologies, deep sequencing, among others.
Towards the development of new technologies
The Partnership for Dengue Control (PDC) wishes to cast a wider net to facilitate and expedite the development of the most promising technologies that are urgently needed not only for pressing research questions but also to be rolled out in affected countries. The Flavivirus field can learn from cutting-edge technologies that have been developed for diseases such as HIV, malaria and Tuberculosis. Hence the workshop is organized around three questions:
What is the current status of Zika and dengue diagnostics?
What new technologies might be available in the near, intermediate and long-term future?
What is needed to make these technologies available?
Chairs
May Chu, Colorado School of Public Health, Clinical Professor
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Scientific Committee
Arlene Chua, World Health Organization, Technical Consultant
Duane Gubler, Duke-NUS Medical School, Emeritus Professor
Eva Harris, University of California, Berkeley, Professor
Aravinda de Silva, University of North Carolina School of Medicine, Professor
Bernadette Murgue, WHO, R&D Blueprint manager
Maurine Murtagh, The Murtagh Group, LLC Principal
Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research
Organized by the Partnership for Dengue Control (PDC) and the Mérieux Foundation (France), with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur.
Setting the objectives of the meeting – Annelies Wilder-Smith, PDC
What are the necessary characteristics of diagnostic assays depending on the intended use: case management, surveillance, serosurveys, research studies, intervention trials – Duane Gubler, GDAC
Review of Zika standard assays (CDC MAC, IgG and PRNT) – Aravinda de Silva for Amy Lambert, CDC
Landscape analysis of the current status of Flavivirus diagnostics (dengue and Zika) – Maurine Murtagh, The Murtagh Group
Coffee break
3.30pm – 5pm
Session 2
Chairs: Francis Moussy, Amy Lambert
Learning from successful novel technologies that made it to the market – Mark Miller, BioMerieux
Demand forecasting and market considerations – Nagwa Hasanin, UNICEF
Learning from past emergency authorizations – Elliot Cowan, Partners in Diagnostics
Networking session
6.00pm – 7.00pm
Evening Chair: May ChuTalk: Zika and dengue diagnostics from a strategic investor’s perspective – Julie Schäfer, BARDA
Cocktail Dinner
Wednesday, May 3 – Day 2
Where do we go? Technological innovations in Flavivirus diagnostics
8.30am – 12.30pm
Session 3: Detecting acute infection
Chairs: Maurine Murtagh, Arlene Chua
Imminent technological innovations
Cutting edge innovations for the intermediate and long-term future
Discussion
8.30am – 10.00am
Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University
Development of molecular tests for management of febrile illnesses and diagnosis of viral haemorrhagic fever – Kevin Arien, ITM
Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore
Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences
Coffee break
10.30am – 12.30pm
Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene
NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH
Application of a parsimonious targeted-enrichment methodology for full-genome sequencing of viral genomes directly from patient samples – October Sessions, Duke-NUS
Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS
Multiplex magneto-optical detection technique – John Lewandowski, MIT
Discussion
Lunch
2pm – 5.45pm
Session 4: Detecting past infections
Chairs: Eva Harris, Aravinda de Silva
2pm – 3.40pm
Dx antigen discovery and imminent technological innovations
New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC
NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA
In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University
Structure based design of novel Zika virus antigens for serodiagnosis – Prem Lakshmanane, UNC-CH, North Carolina
Coffee Break
4.00pm – 5.00pm
Cutting Edge Innovations For The Intermediate And Long-Term Future
VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux
VIRO-TRACK – A rapid, quantitative, and accurate dengue/zika diagnostics platform for point of care use in endemic regions – Filippo Giacomo Bosco, BluSense Diagnostics ApS
A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA
5.00pm – 5.45pm
Discussion
BBQ
Thursday, May 4 – Day 3
How do we make it happen? From idea to market
8.30am – 10am
Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response
Chairs: Bill Rodriguez, Bernadette Murgue
Preparing for the inevitable: open platform technologies for rapid outbreak response
WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint
Diagnostics preparedness platform – Thomas Ullrich, Alere
Learning from influenza POCT – Julie Schäfer, BARDA
Genetic analysis tool kit for rapid outbreak response – Michael Baffi, Thermo Fisher
Coffee break
10.30am – 12.30pm
Session 6: Critical steps to ensure quality products
Chairs: Rosanna Peeling, Piero Olliaro
Critical steps to ensure quality products – Bill Rodriguez
Lessons learnt on bringing diagnostics to the market in low and middle income countries – Cassandra Kelly, FIND
Two new WHO IVD initiatives: SAGE-IVD and EDL – Francis Moussy, WHO Blueprint
Regional regulatory harmonization working parties – Rosanna Peeling, LSHTM
Streamlining from bench-to-bedside – Piero Olliaro, WHO TDR
Panel Discussion
Lunch
1.30pm – 3:30pm
Session 7: Identifying PDC’s roles to support innovative diagnostics
Chairs: May Chu, Julie Schäfer
Panel 1: Networks and alliances – Dhamari Naidoo, WHO; Maria Guzman, RELDA Cuba; Amadou Sall, Institute Pasteur Senegal; Francois Xavier Babin, Merieux (Networks of Laboratories);
Annelies Wilder-Smith and In-Kyu Yoon, GDAC
Panel 2: Accelerating from ideas to market – Jennifer Fluder, USAID; Rosanna Peeling, LSHTM; Thomas Ullrich, Alere
Panel 3: Views from stakeholders and partners – Sumi Paranjape, Vulcan; Nagwa Hasanin, UNICEF; Julie Schäfer, BARDA
Concluding Discussion: research agenda and roadmap for the next 12 months
3.30pm – 4pm
Summary and Recommendations – May Chu, Rosanna Peeling and Annelies Wilder-Smith
We use cookies to ensure you have the best experience on our website. If you continue to use them, we will consider that you accept the use of cookies.Ok
